OKYO Pharma LimitedNASDAQ: OKYO

OKYO Pharma Ltd (NASDAQ:OKYO) has postponed its Key Opinion Leader event on the Phase 2 trial results of OK-101 in dry eye disease from April 9 to May 2024 in order to include more analyses of its clinical data for presentation at future ophthalmic conferences.

OKYO Pharma Ltd (NASDAQ:OKYO) unveiled new results showing its lead drug OK-101 has shown significant and measurable improvements in various indicators and symptoms associated with Dry Eye Disease (DED) during its initial Phase 2 trial involving human participants. These improvements include notably reducing ocular pain, which suggests potential efficacy in treating DED.

OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to host a Key Opinion Leader (KOL) event on April 9 following the anticipated release of comprehensive efficacy data from its Phase 2 trial of OK-101 in dry eye disease (DED) on March 22. The event, scheduled to start at 12pm ET is poised to offer a detailed exploration of the trial's findings, featuring presentations from renowned specialists, including Jay Pepose and Anat Galor.

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of its investigational therapeutic OK-101 in dry eye disease on Friday, March 22, with plans to advance the drug into Phase 3 trials later in 2024. The company said it will host a Key Opinion Leader event to go over its Phase 2 study results, featuring prominent experts in the field of dry eye disease who will provide insights on the clinical significance of the findings and the potential implications for patient care and future research.

OKYO Pharma Ltd (NASDAQ:OKYO) shares moved higher ahead of Friday's opening bell after the biopharmaceutical firm announced that the US Food and Drug Administration (FDA) has cleared its first Investigational New Drug (IND) application for its drug candidate OK-101 for the treatment of neuropathic corneal pain. The company can now progress with a Phase 2 study comparing OK-101 to placebo in neuropathic corneal pain patients which is scheduled to begin in the second quarter of 2024.

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has appointed three prominent ophthalmologists and corneal surgeons to its Scientific Advisory Board to advise management on the development of its therapeutic OK-101 for the treatment of dry eye disease and neuropathic corneal pain. Dr.

OKYO Pharma Ltd (NASDAQ:OKYO) has announced positive safety and efficacy results in its Phase 2 trial of OK-101 ophthalmic solution for the treatment of inflammatory dry eye disease (DED). The trial, conducted at six US sites with 240 subjects, demonstrated promising outcomes and established a clear path for Phase 3 registration trials.

LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, is pleased to announce that it will be presenting at Biotech Showcase in San Francisco, January 8-10 2024. The OKYO management team will also be participating in one-on-one partnering meetings throughout the conference.

OKYO Pharma Ltd (NASDAQ:OKYO) told investors that it is on track to release top-line results from its phase 2 clinical trial of OK-101 to treat dry eye disease (DED) this month after the last patient completed the 12-week OK-101 dosing study. The clinical-stage drug developer said data analysis plans for the 240-patient double-blind placebo-controlled trial have now been finalized and submitted to the US Food and Drug Administration (FDA) for feedback, in anticipation of database lock, subsequent data analysis, and reporting of top-line findings on OK-101.